Acute onset of ovarian dysfunction in young females after start of cancer treatment.
(2013) In Pediatric Blood & Cancer 60(4). p.676-681- Abstract
- BACKGROUND:
Female childhood cancer survivors are at risk of ovarian failure and premature ovarian insufficiency. We hereby present an interim analysis of a prospective observational study of ovarian function during cancer treatment of young females in relation to clinical factors.
PROCEDURE: Thirty-four consecutive female cancer patients aged 0-18 year were included after informed consent. Serum/Plasma levels of anti-Müllerian hormone (AMH), inhibin B, FSH, LH, and oestradiol (E2) were measured at diagnosis and every 3-4 months during and after treatment.
RESULTS: All patients had detectable AMH levels at diagnosis. Eleven patients had reached menarche (mean age 14½ years) and the... (More) - BACKGROUND:
Female childhood cancer survivors are at risk of ovarian failure and premature ovarian insufficiency. We hereby present an interim analysis of a prospective observational study of ovarian function during cancer treatment of young females in relation to clinical factors.
PROCEDURE: Thirty-four consecutive female cancer patients aged 0-18 year were included after informed consent. Serum/Plasma levels of anti-Müllerian hormone (AMH), inhibin B, FSH, LH, and oestradiol (E2) were measured at diagnosis and every 3-4 months during and after treatment.
RESULTS: All patients had detectable AMH levels at diagnosis. Eleven patients had reached menarche (mean age 14½ years) and the remaining patients had a mean age of 6½ years. They all showed a rapid decline in AMH after 3 months of treatment, regardless of AMH at diagnosis, age, menarche, or treatment given. Those given radiotherapy below the diaphragm and/or stem cell transplantation (SCT) (n = 9) had no ovarian recovery during or 1½-year after treatment. However, recovery was observed in those given standard treatment for acute lymphatic leukemia (n = 7) already during maintenance chemotherapy. For the remaining patients, longer follow-up is required for analysis of ovarian recovery after treatment.
CONCLUSIONS: Rapid ovarian dysfunction is observed in all females after initiation of cancer treatment as measured by AMH and inhibin B. Our data regarding those who require abdominal radiotherapy and/or SCT confirms the recommendations in the Nordic countries where these patients are eligible for cryopreservation of ovarian cortical tissue before start of cancer treatment. Pediatr Blood Cancer © 2012 Wiley Periodicals, Inc. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3123610
- author
- Mörse, Helena LU ; Elfving, Maria LU ; Lindgren, Anna LU ; Wölner-Hanssen, Pål LU ; Andersen, Claus Yding and Øra, Ingrid LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Pediatric Blood & Cancer
- volume
- 60
- issue
- 4
- pages
- 676 - 681
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- wos:000316291400027
- pmid:23015461
- scopus:84873710424
- pmid:23015461
- ISSN
- 1545-5017
- DOI
- 10.1002/pbc.24327
- language
- English
- LU publication?
- yes
- id
- 2cf97449-3b29-4514-9e48-33b716150a03 (old id 3123610)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23015461?dopt=Abstract
- date added to LUP
- 2016-04-01 10:22:58
- date last changed
- 2022-04-12 05:43:33
@article{2cf97449-3b29-4514-9e48-33b716150a03,
abstract = {{BACKGROUND: <br/><br>
Female childhood cancer survivors are at risk of ovarian failure and premature ovarian insufficiency. We hereby present an interim analysis of a prospective observational study of ovarian function during cancer treatment of young females in relation to clinical factors. <br/><br>
<br/><br>
PROCEDURE: Thirty-four consecutive female cancer patients aged 0-18 year were included after informed consent. Serum/Plasma levels of anti-Müllerian hormone (AMH), inhibin B, FSH, LH, and oestradiol (E2) were measured at diagnosis and every 3-4 months during and after treatment. <br/><br>
<br/><br>
RESULTS: All patients had detectable AMH levels at diagnosis. Eleven patients had reached menarche (mean age 14½ years) and the remaining patients had a mean age of 6½ years. They all showed a rapid decline in AMH after 3 months of treatment, regardless of AMH at diagnosis, age, menarche, or treatment given. Those given radiotherapy below the diaphragm and/or stem cell transplantation (SCT) (n = 9) had no ovarian recovery during or 1½-year after treatment. However, recovery was observed in those given standard treatment for acute lymphatic leukemia (n = 7) already during maintenance chemotherapy. For the remaining patients, longer follow-up is required for analysis of ovarian recovery after treatment. <br/><br>
<br/><br>
CONCLUSIONS: Rapid ovarian dysfunction is observed in all females after initiation of cancer treatment as measured by AMH and inhibin B. Our data regarding those who require abdominal radiotherapy and/or SCT confirms the recommendations in the Nordic countries where these patients are eligible for cryopreservation of ovarian cortical tissue before start of cancer treatment. Pediatr Blood Cancer © 2012 Wiley Periodicals, Inc.}},
author = {{Mörse, Helena and Elfving, Maria and Lindgren, Anna and Wölner-Hanssen, Pål and Andersen, Claus Yding and Øra, Ingrid}},
issn = {{1545-5017}},
language = {{eng}},
number = {{4}},
pages = {{676--681}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Pediatric Blood & Cancer}},
title = {{Acute onset of ovarian dysfunction in young females after start of cancer treatment.}},
url = {{http://dx.doi.org/10.1002/pbc.24327}},
doi = {{10.1002/pbc.24327}},
volume = {{60}},
year = {{2013}},
}